ING Groep NV acquired a new stake in NuVasive, Inc. (NASDAQ:NUVA) during the second quarter, Holdings Channel reports. The firm acquired 6,164 shares of the medical device company’s stock, valued at approximately $474,000.

Other institutional investors also recently modified their holdings of the company. Miles Capital Inc. raised its position in shares of NuVasive by 0.3% in the first quarter. Miles Capital Inc. now owns 3,118 shares of the medical device company’s stock valued at $233,000 after buying an additional 8 shares in the last quarter. US Bancorp DE raised its position in shares of NuVasive by 1.7% in the first quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after buying an additional 41 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its position in shares of NuVasive by 0.5% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 8,720 shares of the medical device company’s stock valued at $651,000 after buying an additional 43 shares in the last quarter. World Asset Management Inc raised its position in shares of NuVasive by 2.3% in the first quarter. World Asset Management Inc now owns 3,117 shares of the medical device company’s stock valued at $233,000 after buying an additional 69 shares in the last quarter. Finally, Keybank National Association OH raised its position in shares of NuVasive by 0.7% in the first quarter. Keybank National Association OH now owns 12,667 shares of the medical device company’s stock valued at $946,000 after buying an additional 86 shares in the last quarter.

Shares of NuVasive, Inc. (NASDAQ:NUVA) traded up 3.51% during midday trading on Friday, hitting $65.79. 1,312,207 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $76.85 and its 200-day moving average is $74.43. NuVasive, Inc. has a 1-year low of $56.70 and a 1-year high of $81.68. The stock has a market cap of $3.34 billion, a PE ratio of 103.61 and a beta of 1.06.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. The firm had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. NuVasive’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.40 earnings per share. Analysts predict that NuVasive, Inc. will post $2.00 earnings per share for the current fiscal year.

WARNING: “6,164 Shares in NuVasive, Inc. (NASDAQ:NUVA) Acquired by ING Groep NV” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/08/06/6164-shares-in-nuvasive-inc-nasdaqnuva-acquired-by-ing-groep-nv.html.

Several equities analysts have recently commented on the stock. Jefferies Group LLC restated a “buy” rating and issued a $84.00 price objective on shares of NuVasive in a report on Friday, June 30th. Cowen and Company restated an “outperform” rating and issued a $85.00 price objective on shares of NuVasive in a report on Monday, May 15th. Royal Bank Of Canada restated a “buy” rating and issued a $85.00 price objective on shares of NuVasive in a report on Thursday, July 20th. TheStreet upgraded shares of NuVasive from a “c+” rating to a “b” rating in a report on Wednesday, May 3rd. Finally, Zacks Investment Research upgraded shares of NuVasive from a “sell” rating to a “hold” rating in a report on Tuesday, July 4th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $81.18.

In other NuVasive news, EVP Peter Michael Leddy purchased 7,850 shares of NuVasive stock in a transaction on Tuesday, August 1st. The shares were purchased at an average cost of $63.88 per share, with a total value of $501,458.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 4.70% of the company’s stock.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.